
NavDx
Optimizing HPV+ Cancer Care



NavDx® Surveillance Testing Program

The Surveillance Testing Program combines clinical flexibility, operational simplicity, and patient-centered access to support long-term post-treatment recurrence monitoring for HPV+ head & neck and anal squamous cell cancer. With a single, annual test order that covers a full 12 months of testing, providers and patients are set up to successfully remain on track while experiencing benefits that can't be achieved with typical recurrence monitoring. Start any time; no baseline/pre-treatment test is required to use the NavDx test for surveillance monitoring.

How the Program Works

1



Healthcare provider places one annual test order with provider-directed cadence

Providers place a single NavDx test order that covers a 12-month period.

Testing frequency (e.g., every 3, 4, or 6 months) is set by the provider based on clinical need and can be adjusted at any time.

2



Provider selects phlebotomy options

In addition to blood draws at the provider's office/facility, our Patient Navigation team can arrange blood draws at convenient locations for patients. ***When NavDx Phlebotomy Services are used, patients are more likely to complete testing compared to relying on in-office/facility blood draws (data on file).***

3



Receive test results prior to patient office visits

Providers generally receive results within 7 business days of the specimen being received in our laboratory.

When NavDx Phlebotomy Services are used, testing can be completed in advance and providers can have test results available at the time of their follow-up appointments.

4



Reduce administrative burden and improve patient compliance

With NavDx Phlebotomy Services, we will actively help your patients stay on schedule. As their next testing period approaches, our in-house Patient Navigation Team will reach out to patients to schedule their blood draw and help them stay on track with their surveillance plan.

Flexible Phlebotomy Options

Patient-centered blood draw options reduce barriers to testing adherence:

- At-home phlebotomy
- Workplace blood draws
- Blood draws at a location convenient for the patient, including local walk-in clinics

Benefits for Physicians

- Reduced administrative burden: No need to place multiple test orders
- Maintain provider control over testing cadence and clinical decisions
- Improved patient adherence to long-term monitoring

Benefits for Patients

- Convenient blood draw options that offer minimal disruption to daily life
- Clear and consistent post-treatment surveillance plan
- Fewer barriers to testing and reduced chance of missed tests

A growing number of commercial insurance companies cover NavDx testing. Coverage varies based on insurance and service type. NavDx testing is a covered benefit for Medicare patients when monitoring for HPV+ anal or oropharyngeal cancer recurrence. Medicare covers four tests annually during OPSCC surveillance in the first two years post-treatment, and two tests annually thereafter, up to five years post-treatment. For ASCC surveillance, Medicare covers four tests annually in the first three years post-treatment, and two tests annually thereafter, up to five years post-treatment.

Learn more about NavDx testing.

CareDx

© 2026 Naveris (now part of CareDx) 21 Hickory Drive, Suite 600, Waltham, MA 02451 | www.naveris.com | clinops@naveris.com
US Patents 11,254,989 and 11,168,373 | NavDx-0126-262R1.5